Medical disclaimer: This article represents the editorial opinion of The Ivermectin Review and aggregated reader experiences. It is not medical advice. We are not doctors. The ivermectin + mebendazole protocol is not approved by any regulatory body as a cancer treatment. Always consult your oncologist before starting any new protocol. Results reported by readers are anecdotal and individual results will vary significantly.
What is the Ivermectin + Mebendazole protocol?
The Ivermectin + Mebendazole (IVM+MBZ) protocol is the combined use of two antiparasitic drugs — ivermectin and mebendazole — that have been explored by researchers and patients for potential anti-cancer properties. Both drugs are well-established, widely available, and have long safety records in their approved antiparasitic uses.
The protocol is sometimes referred to in the context of broader "repurposed drug" approaches to cancer, alongside other agents such as fenbendazole, low-dose naltrexone, and dichloroacetate. It is increasingly discussed in integrative oncology communities and has attracted attention from both patients and researchers.
"In our view, the IVM+MBZ protocol represents one of the more promising areas of repurposed drug research in oncology. The mechanistic rationale is plausible, early observational data is encouraging, and the safety profile of both drugs is well established. That said, controlled clinical trial data remains limited and we urge caution. This is not a proven cancer treatment."
What does the evidence say?
It is important to be honest about the current state of evidence. This is an emerging area of research — not a proven treatment. Here is a fair summary of what is and is not known:
- Preclinical data: Multiple laboratory studies have identified anti-proliferative effects of both ivermectin and mebendazole on cancer cell lines. This is promising but does not confirm human efficacy.
- Observational data: Several observational studies and case series have reported clinical benefit in patients using these agents alongside or independently of conventional treatment. These are not randomised controlled trials.
- Mechanistic rationale: Both drugs appear to interfere with cancer cell division through different mechanisms — mebendazole via tubulin disruption, ivermectin via multiple proposed pathways including PAK1 inhibition.
- Clinical trials: A small number of early-phase clinical trials have been initiated or completed. Results are preliminary.
- What is missing: Large-scale, well-funded, randomised controlled trials. Without these, definitive conclusions cannot be drawn.
What our readers report
The following are a selection of reader-submitted reviews. These are personal opinions and anecdotal experiences — not clinical evidence. Results vary significantly.
"Used the TWC protocol for 4 months alongside standard treatment, monitored by my oncologist throughout. Tumour markers improved and I felt noticeably better in terms of energy. Can't attribute it entirely to this but I'm continuing."
"My father started this after his oncologist declined further chemo. Hard to measure objectively but he felt better, had more appetite, and scans at 6 months showed stability rather than progression. We're cautiously encouraged."
"Tried for 3 months. I didn't notice dramatic changes but also no side effects. It's hard to know what to attribute to what when you're doing multiple things at once. I'm still using it but managing expectations."
Important considerations
Drug interactions: Both ivermectin and mebendazole can interact with other medications. It is essential to inform your oncologist and pharmacist if you are considering this protocol.
Dosing: Dosing protocols vary widely in the literature and among practitioners. There is no universally agreed protocol. Self-medicating without medical supervision carries risk.
Source and quality: The quality of ivermectin and mebendazole products varies significantly. We recommend only pharmaceutical-grade, compounded formulations from reputable providers.
This is not a cure: Nothing on this site suggests or implies that this protocol cures cancer. Reader reports of positive outcomes are anecdotal. Always maintain your conventional treatment plan unless advised otherwise by your oncologist.
Cancer research & studies
Below is a curated list of published and submitted research relevant to ivermectin, mebendazole, and fenbendazole in cancer contexts. We link to original sources where available. This is not an exhaustive list and does not constitute an endorsement of any findings.
Multiple laboratory studies have demonstrated ivermectin's ability to inhibit cancer cell proliferation across breast, colon, lung, and cervical cancer cell lines via PAK1 inhibition and other mechanisms.
Search PubMed →Mebendazole has been studied in several early-phase clinical and observational contexts, particularly in colorectal cancer and glioblastoma. Works by disrupting tubulin polymerisation in cancer cells.
Search PubMed →Fenbendazole, a veterinary antiparasitic, gained significant attention following Joe Tippens' widely reported case. Subsequent research has examined its mechanisms including p53 stabilisation and glucose uptake inhibition.
Search PubMed →A growing body of systematic review literature examines the rationale for drug repurposing in oncology, with antiparasitic agents featuring prominently due to their established safety profiles and proposed anti-cancer mechanisms.
Search PubMed →What people are saying
Latest posts from patients, researchers, and practitioners discussing the IVM+MBZ protocol on X (Twitter). Posts are from third parties and do not represent the views of The Ivermectin Review.
Our verdict
"Cautiously promising. The mechanistic rationale is credible, the safety profile is well-established, and reader-reported experiences are largely positive. However, the absence of large-scale clinical trial data means we cannot recommend this as a standalone treatment. In our opinion, this is best explored as a complementary approach alongside — not instead of — conventional oncology care, with full transparency to your medical team."